CJC-1295 (Without DAC) (10mg)

# CJC-1295 (No DAC) - GHRH Analog Research Peptide

## SCIENTIFIC OVERVIEW
CJC-1295 without DAC (Drug Affinity Complex) is a synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH), also known as Modified GRF(1-29) or Mod GRF 1-29. This peptide differs from native GHRH through four amino acid substitutions that enhance stability against enzymatic degradation while maintaining pituitary receptor affinity.

## RESEARCH APPLICATIONS
Scientific studies have explored CJC-1295 (no DAC) for:
- Growth hormone-releasing hormone receptor (GHRHR) binding studies
- Pulsatile GH secretion research
- Somatotroph cell activation analysis
- DPP-IV enzyme resistance studies
- Growth hormone secretagogue synergy research (with GHRP compounds)
- Hypothalamic-pituitary axis pathway analysis
- Age-related GH decline research models
- Sleep-wake cycle and GH pulse research

## PRODUCT SPECIFICATIONS
- **Purity:** ≥98% (HPLC Verified)
- **Form:** Sterile Lyophilized Powder
- **Alternative Names:** Modified GRF(1-29), Mod GRF 1-29
- **Sequence:** 29 amino acids (GHRH analog with 4 substitutions)
- **Molecular Formula:** C₁₅₂H₂₅₂N₄₄O₄₂
- **Molecular Weight:** ~3,367 Da
- **CAS Number:** 863288-34-0
- **Appearance:** White to off-white powder
- **Storage:** -20°C (freezer), desiccated
- **Reconstitution:** Bacteriostatic water
- **Stability:** 24 months frozen; 30 days at 2-8°C reconstituted

## STRUCTURAL MODIFICATIONS
Four key amino acid substitutions from native GHRH(1-29):
1. **Tyr¹ → D-Ala²** - Enhanced stability
2. **Ala⁸ → Gln⁸** - Reduced DPP-IV cleavage
3. **Ala¹⁵ → Leu¹⁵** - Improved receptor binding
4. **Leu²⁷ → Leu²⁷** - Enhanced half-life

Result: ~30-minute half-life vs. <7 minutes for native GHRH

## QUALITY ASSURANCE
✓ RP-HPLC purity ≥98%  
✓ Mass spectrometry confirmation  
✓ Amino acid composition analysis  
✓ Peptide content assay (>85%)  
✓ Endotoxin: <1.0 EU/mg  
✓ DPP-IV resistance verification  
✓ pH: 5.5-7.0 (reconstituted)  
✓ Sterility: USP <71> compliant  

## MECHANISM OF ACTION (Research Models)
CJC-1295 (no DAC) binds to GHRH receptors on anterior pituitary somatotrophs, triggering:
- cAMP/PKA signaling cascade activation
- Calcium influx via voltage-gated channels
- Growth hormone granule exocytosis
- Pulsatile GH release (maintains physiological pattern)

## CJC-1295 vs. CJC-1295 WITH DAC
**NO DAC (This Product):**
- Shorter half-life (~30 minutes)
- Pulsatile GH release (physiological)
- Multiple daily administrations in research
- Better synergy with GHRP peptides
- More closely mimics natural GHRH pulses

**WITH DAC:**
- Extended half-life (6-8 days)
- Sustained GH elevation
- Once-weekly administration in studies
- Less physiological GH pattern

## RECONSTITUTION GUIDELINES
1. Use bacteriostatic water (0.9% benzyl alcohol)
2. Typical concentration: 1-2 mg/mL for research
3. Add water slowly down vial wall
4. Swirl gently (do not shake vigorously)
5. Allow complete dissolution (2-5 minutes)
6. Inspect for clarity and absence of particulates
7. Store reconstituted solution at 2-8°C

## RESEARCH SYNERGY STUDIES
Published research demonstrates enhanced effects when combined with:
- **Ipamorelin** (GHRP-like compound)
- **GHRP-2 or GHRP-6** (ghrelin mimetics)
- **Hexarelin** (synthetic hexapeptide)

Mechanism: Dual pathway activation (GHRH + ghrelin receptor)

## STABILITY DATA
- **Lyophilized:** Stable 24+ months at -20°C
- **Room temperature:** Stable 90 days (sealed, desiccated)
- **Reconstituted:** 30 days at 2-8°C in bacteriostatic water
- **pH sensitivity:** Most stable pH 5-7
- **Light:** Minimal photodegradation, but protect from direct light

## SCIENTIFIC BACKGROUND
Developed in the early 2000s to overcome limitations of native GHRH. Over 50 published studies have explored CJC-1295 (no DAC) in various research contexts including aging, metabolism, and growth hormone physiology.

## HANDLING PRECAUTIONS
Use aseptic technique during reconstitution. Work in clean environment or biosafety cabinet. Avoid contamination from non-sterile surfaces. Use sterile syringes and needles for all handling.

## COMPARATIVE PEPTIDE RESEARCH
**vs. Sermorelin:** Similar mechanism but enhanced stability (4x longer half-life)

**vs. CJC-1295 DAC:** Shorter duration, maintains pulsatile pattern

**vs. Native GHRH:** Dramatically improved resistance to DPP-IV degradation

## FOR RESEARCH PURPOSES ONLY
This product is intended strictly for in-vitro research and laboratory animal studies. Not for human consumption or clinical use. Not approved by FDA or other regulatory agencies for therapeutic applications.

---

**DISCLAIMER:** By purchasing, you certify you are conducting legitimate scientific research under appropriate institutional oversight. Purchaser assumes all responsibility for compliance with applicable laws, regulations, and biosafety protocols.